Experimental cancer treatments for advanced stages are more effective than previously thought. Some oncology practitioners believe that experimental drugs are harmful - they give false hope to patients because of its low efficiency (long anticipated effectiveness of the experimental treatment with special drugs produced in Canadian pharmacy only at the level of 4-6% of cases). Patients in the final stage of the disease should have greater access to information about the experimental treatment programs, and, accordingly, they and their families should have the right to know what their real chances, with a particular treatment strategy. Scientists believe that the involvement of cancer patients even in the early stages of clinical trials can be very useful for them. Besides, the search for a way out of the situation means continuing the fight against the disease. It is characterized by academic phrase "treatment of metastatic cancer still remains palliative, with a very low probability of complete remission and cure the disease."
 

Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology

Objectives: The Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology (MCMCC) will take part in the clinical trial IMMOMEC. To the scientific part, MCMCC will cooperate in comprehensive research on biomarkers for clinical and immunological treatment responses.

Expertise relevant to the proposed work: Expertise relevant to the proposed work: MCMCC is the leading Polish comprehensive cancer center, as well as the primary government research institution devoted solely to oncology. Founded in 1932 by Maria Sklodowska-Curie, and currently it is divided into 9 specialized clinical departments responsible for the diagnostics and therapy of different tumor types. The research departments are devoted to experimental therapies, epidemiology and prevention, pathology, imaging and basic research in the cancer biology. In 2011, in MCMCC, 28000 patients were treated the inpatient clinics; another 26000 patients – in the One Day Chemotherapy Section, and as more than 340 000 outpatient visits were recorded.

The Department of Soft Tissue/Bone Sarcoma and Melanoma, MCMCC is the major Polish comprehensive center in the field of the treatment and research in sarcoma and melanoma. In MCMCC approximately 300 new cases of melanoma and more than 10 patients with Merkel Cell Carcinoma are treated in combined modalities every year. MCMCC has participated in numerous clinical trials (phase II and III) and translational research in close cooperation with international research groups, e.g.: EORTC Soft Tissue and Bone Sarcoma Group (e.g. EORTC 62027, 62024) and EORTC Melanoma Group (e.g. EORTC 18952, 18961, 18032), or pharmaceutical-company sponsored (as CAMN107G2201, DERMA). In 1995, MCMCC was the first center in Poland to introduce sentinel lymph node biopsy in the clinical management of cutaneous melanoma into everyday practice. MCMCC also participates in preparing both Polish and international recommendations for sarcoma and melanoma patients.

Specific role in the project: MCMCC will actively contribute patients with Merkel cell carcinoma to the clinical trial as well as dissemination of the final results of our projects; thus MCMCC is involved in WP1 and WP2.

www.coi.pl


Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology
Department of Soft Tissue/Bone Sarcoma and Melanoma
Roentena 5
02-781 Warsaw
Poland